INTERVENTION 1:	Intervention	0
Surgery and Chemotherapy	Intervention	1
surgery	OAE:0000067	0-7
Eligible patients had undergone surgery and chemotherapy for high risk breast cancer, defined as either a T3 or T4 primary tumor, or N2 by either clinical or pathological criteria.	Intervention	2
surgery	OAE:0000067	32-39
breast cancer	DOID:1612	71-84
capecitabine	Intervention	3
capecitabine	CHEBI:31348	0-12
adjuvant therapy	Intervention	4
adjuvant	CHEBI:60809	0-8
radiation therapy	Intervention	5
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Histologically or cytologically confirmed invasive adenocarcinoma of the breast, meeting 1 of the following high-risk criteria:	Eligibility	1
adenocarcinoma	DOID:299	51-65
breast	UBERON:0000310	73-79
T3 or T4 primary tumor	Eligibility	2
4 or more involved axillary lymph nodes (N2 nodal stage)	Eligibility	3
lymph	UBERON:0002391	28-33
Completed surgical excision	Eligibility	4
No immediate reconstruction with autologous flap reconstruction	Eligibility	5
Patients having tissue expanders or implants placed prior to radiation may be enrolled at the physician's discretion	Eligibility	6
tissue	UBERON:0000479	16-22
No residual breast cancer	Eligibility	7
breast cancer	DOID:1612	12-25
Microscopically positive margins are allowed if a re-excision is not felt to be clinically justified	Eligibility	8
Candidate for radiotherapy	Eligibility	9
radiotherapy	OAE:0000235	14-26
Must not require bilateral radiotherapy	Eligibility	10
bilateral	HP:0012832	17-26
radiotherapy	OAE:0000235	27-39
No metastatic (stage IV) breast cancer by AJCC staging criteria	Eligibility	11
breast cancer	DOID:1612	25-38
Hormone receptor status not specified	Eligibility	12
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
No CNS disorders	Eligibility	13
PATIENT CHARACTERISTICS:	Eligibility	14
patient	HADO:0000008,OAE:0001817	0-7
Life expectancy  6 months	Eligibility	15
Karnofsky performance status 70-100%	Eligibility	16
Menopausal status not specified	Eligibility	17
Ambulatory	Eligibility	18
Hemoglobin > 9 g/dL	Eligibility	19
hemoglobin	CHEBI:35143	0-10
Platelet count > 100,000/mm³	Eligibility	20
platelet count	CMO:0000029	0-14
ANC > 1,500/mm³	Eligibility	21
Serum AST, ALT, and alkaline phosphatase  2 times upper limit of normal (ULN)	Eligibility	22
phosphatase	GO:0016791,BAO:0000295	29-40
Total bilirubin normal	Eligibility	23
Creatinine clearance > 50 mL/min	Eligibility	24
creatinine clearance	CMO:0000765	0-20
Negative pregnancy test	Eligibility	25
Not pregnant or nursing	Eligibility	26
Fertile patients must use effective contraception during study and for 30 days after the last study drug administration	Eligibility	27
drug administration	OAE:0000011	100-119
No serious, uncontrolled, concurrent infection(s)	Eligibility	28
No diabetes with current or history of delayed wound healing or skin ulcers	Eligibility	29
history	BFO:0000182	28-35
wound healing	GO:0042060	47-60
No autoimmune connective tissue disorder	Eligibility	30
connective tissue	UBERON:0002384	14-31
disorder	OGMS:0000045	32-40
No prior unanticipated severe reaction to fluoropyrimidine therapy, known sensitivity to 5-fluorouracil, or known dihydropyrimidine dehydrogenase (DPD) deficiency	Eligibility	31
severe	HP:0012828	23-29
5-fluorouracil	CHEBI:46345	89-103
No other carcinomas within the last five years except cured non-melanoma skin cancer and in-situ cervical cancer	Eligibility	32
skin cancer	DOID:4159	73-84
cervical cancer	DOID:4362	97-112
No clinically significant cardiac disease (e.g., congestive heart failure, symptomatic coronary artery disease, or cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months	Eligibility	33
disease	DOID:4,OGMS:0000031	34-41
disease	DOID:4,OGMS:0000031	103-110
congestive heart failure	HP:0001635,DOID:6000	49-73
coronary artery disease	DOID:3393	87-110
myocardial infarction	HP:0001658,DOID:5844	175-196
No other serious uncontrolled medical conditions that the investigator feels might compromise study participation, including any of the following:	Eligibility	34
Uncontrolled seizures	Eligibility	35
Psychiatric disability judged by the investigator to be clinically significant	Eligibility	36
Physically intact upper gastrointestinal tract	Eligibility	37
No malabsorption syndrome	Eligibility	38
malabsorption	HP:0002024	3-16
syndrome	DOID:225	17-25
No uncompensated coagulopathy	Eligibility	39
No patients whose breast size or body contour puts them at increased risk for skin desquamation from standard radiotherapy	Eligibility	40
breast	UBERON:0000310	18-24
size	PATO:0000117	25-29
radiotherapy	OAE:0000235	110-122
Able to read and speak English	Eligibility	41
PRIOR CONCURRENT THERAPY:	Eligibility	42
Fully recovered from surgery and chemotherapy with completely healed surgical wounds	Eligibility	43
surgery	OAE:0000067	21-28
At least 4 weeks since completion of prior chemotherapy regimen, excluding trastuzumab (Herceptin®)	Eligibility	44
Concurrent trastuzumab allowed at the physician's discretion	Eligibility	45
More than 4 weeks since prior participation in any investigational drug study	Eligibility	46
drug	CHEBI:23888	67-71
At least 4 weeks since prior and no concurrent sorivudine or brivudine	Eligibility	47
sorivudine	CHEBI:32152	47-57
More than 2 weeks since prior major surgery	Eligibility	48
surgery	OAE:0000067	36-43
No prior capecitabine	Eligibility	49
capecitabine	CHEBI:31348	9-21
No prior radiotherapy to the chest or ipsilateral lymphatics	Eligibility	50
radiotherapy	OAE:0000235	9-21
chest	UBERON:0001443	29-34
No concurrent hormonal therapy during course of chemotherapy or radiation therapy	Eligibility	51
No concurrent allopurinol or cimetidine	Eligibility	52
allopurinol	CHEBI:40279	14-25
cimetidine	CHEBI:3699	29-39
Concurrent coumadin is allowed	Eligibility	53
Outcome Measurement:	Results	0
Overall Safety	Results	1
Primarily Grade 1 and 2 toxicities attributable to capecitabine	Results	2
capecitabine	CHEBI:31348	51-63
Time frame: 1 year	Results	3
time	PATO:0000165	0-4
year	UO:0000036	14-18
Results 1:	Results	4
Arm/Group Title: Surgery and Chemotherapy	Results	5
surgery	OAE:0000067	17-24
Arm/Group Description: Eligible patients had undergone surgery and chemotherapy for high risk breast cancer, defined as either a T3 or T4 primary tumor, or N2 by either clinical or pathological criteria.	Results	6
surgery	OAE:0000067	55-62
breast cancer	DOID:1612	94-107
capecitabine	Results	7
capecitabine	CHEBI:31348	0-12
adjuvant therapy	Results	8
adjuvant	CHEBI:60809	0-8
radiation therapy	Results	9
Overall Number of Participants Analyzed: 28	Results	10
Measure Type: Number	Results	11
Unit of Measure: percentage of participants  12.6	Results	12
Adverse Events 1:	Adverse Events	0
Total: 6/39 (15.38%)	Adverse Events	1
Radiation Dermatitis  6/39 (15.38%)	Adverse Events	2
dermatitis	DOID:2723	10-20
